BLU vs. SUPN, PCRX, ABCL, VTYX, CVAC, GERN, SLRN, FGEN, RCKT, and IRWD
Should you be buying BELLUS Health stock or one of its competitors? The main competitors of BELLUS Health include Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), AbCellera Biologics (ABCL), Ventyx Biosciences (VTYX), CureVac (CVAC), Geron (GERN), Acelyrin (SLRN), FibroGen (FGEN), Rocket Pharmaceuticals (RCKT), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
BELLUS Health vs.
Supernus Pharmaceuticals (NASDAQ:SUPN) and BELLUS Health (NASDAQ:BLU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.
99.8% of Supernus Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.1% of BELLUS Health shares are owned by institutional investors. 8.0% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 24.2% of BELLUS Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Supernus Pharmaceuticals has a net margin of 7.79% compared to BELLUS Health's net margin of -578,586.63%. Supernus Pharmaceuticals' return on equity of 5.96% beat BELLUS Health's return on equity.
Supernus Pharmaceuticals has higher revenue and earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Supernus Pharmaceuticals had 3 more articles in the media than BELLUS Health. MarketBeat recorded 3 mentions for Supernus Pharmaceuticals and 0 mentions for BELLUS Health. Supernus Pharmaceuticals' average media sentiment score of 1.41 beat BELLUS Health's score of 0.00 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.
Supernus Pharmaceuticals currently has a consensus target price of $46.00, suggesting a potential upside of 39.56%. BELLUS Health has a consensus target price of $16.50, suggesting a potential upside of 12.94%. Given Supernus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Supernus Pharmaceuticals is more favorable than BELLUS Health.
Supernus Pharmaceuticals received 435 more outperform votes than BELLUS Health when rated by MarketBeat users. Likewise, 73.65% of users gave Supernus Pharmaceuticals an outperform vote while only 65.91% of users gave BELLUS Health an outperform vote.
Supernus Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, BELLUS Health has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500.
Summary
Supernus Pharmaceuticals beats BELLUS Health on 15 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BELLUS Health Competitors List
Related Companies and Tools
